Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Identifying the Lowest Effective Initial Dose of Prednisolone for the Treatment of Subacute Granulomatous Thyroiditis: A Systematic Review and Meta-Analysis

Author(s): Akbar Soltani, Fatemeh Nourani, Sahar Behnam Roudsari, Leila Jouybari, Mobina Fathi, Somayeh Haghighat, Marzieh Hadavi* and Azadeh Aletaha

Volume 17, Issue 2, 2022

Published on: 26 November, 2021

Page: [135 - 143] Pages: 9

DOI: 10.2174/2772432816666211012092112

Price: $65

Abstract

Background: Subacute granulomatous thyroiditis (SAGT) is an inflammatory disease due to viral infections. Glucocorticoids, especially prednisolone (PSL), are one of the first approaches in the treatment of patients with SAGT. To date, no study has determined the lowest effective dose of prednisolone with the lowest recurrence rate in the treatment of SAGT. This study aimed to use meta-analysis methods to identify the appropriate dosage of prednisolone with the lowest recurrence rate in the treatment of patients with SAGT.

Methods: This study was conducted according to the PRISMA checklist in February 2021. Two independent researchers performed a search for relevant literature published before March 2021 in English databases, including Scopus, MEDLINE (via PubMed), Web of Science, Cochrane Library, Google Scholar, EMBASE, and also Persian electronic databases including SID, Iran medex, Magiran, and Irandoc. The search algorithm was initially developed by using a combination of MeSH terms, keywords, and also Boolean operators (“AND”; “OR”; “NOT”): Subacute thyroiditis, De Quervain Thyroiditis, Glucocorticoids, Prednisolone, Recurrence, and Meta-Analysis. All statistical analyses were performed using STATA 15.0 (StataCorp LLC, College Station, TX, USA) and SPSS 17.0. A random-effects model based on Metaprop was applied for the Meta-analysis. To assess heterogeneity between studies, the chi-squared test and I2 index were used, and for evaluating publication bias, funnel plots and Egger tests were performed.

Results: The overall recurrence rate was 14.72% [95% CI: 9.63- 20.58] and there was a significant heterogeneity among the studies [I2 = 69.56%; P=0.000]. To evaluate the lowest effective dose of prednisolone, we divided the studies into two groups based on the mean initial dose of prednisolone: less than or equal to 20 mg/day (group one) and greater than 20 mg/day (group two). The recurrence rate in group 1 was 11% [95% CI: 5.7- 16.2] and in group 2 was 23.6% [95% CI: 11.5- 35.6]. Significant correlations were observed between the initial mean dose of PSL and recurrence rate (r= 0.71; P= 0.013). Begg’s funnel plot had no evidence of publication bias in these studies (p=0.160).

Conclusion: According to the results of this meta-analysis, 15 to 20 mg/day of prednisolone is the most effective dosage with the lowest recurrence rate in the treatment of subacute Granulomatous thyroiditis.

Keywords: Subacute thyroiditis, de quervain thyroiditis, subacute granulomatous thyroiditis, glucocorticoids, prednisolone, recurrence, meta-analysis.

« Previous Next »
Graphical Abstract

[1]
Taous A, Islam MS. Thyroiditis: differential diagnosis and management. Bangladesh j otorhinolaryngol 2010; 16(1): 48-53.
[2]
Bindra A, Braunstein GD. Thyroiditis. Am Fam Physician 2006; 73(10): 1769-76.
[PMID: 16734054]
[3]
Thompson MD, Hendy GN, Percy ME, Bichet DG, Cole DE. G protein-coupled receptor mutations and human genetic disease. Methods Mol Biol 2014; 1175(1): 153-87.
[http://dx.doi.org/10.1007/978-1-4939-0956-8_8] [PMID: 25150870]
[4]
Little JW. Thyroid disorders. Part II: hypothyroidism and thyroiditis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102(2): 148-53.
[http://dx.doi.org/10.1016/j.tripleo.2005.05.070] [PMID: 16876054]
[5]
Sweeney LB, Stewart C, Gaitonde DY. Thyroiditis: an integrated approach. Am Fam Physician 2014; 90(6): 389-96.
[PMID: 25251231]
[6]
Saklamaz A. Is there a drug effect on the development of permanent hypothyroIdIsm In subacute thyroIdItIs? Acta Endocrinol (Bucur) 2017; 13(1): 119-23.
[http://dx.doi.org/10.4183/aeb.2017.119] [PMID: 31149159]
[7]
Nabi G, Rahman N, Azad M, Hassan M, Bonik M. De Quervain s Thyroiditis (sub-acute thyroiditis). Mediscope (Manchester) 2017; 4(1): 35-7.
[http://dx.doi.org/10.3329/mediscope.v4i1.34378]
[8]
Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute thyroiditis after SARS-CoV-2 infection. J Clin Endocrinol Metab 2020; 105(7): 2367-70.
[http://dx.doi.org/10.1210/clinem/dgaa276] [PMID: 32436948]
[9]
Ruggeri RM, Campennì A, Siracusa M, Frazzetto G, Gullo D. Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic. Hormones (Athens) 2021; 20(1): 219-21.
[http://dx.doi.org/10.1007/s42000-020-00230-w] [PMID: 32676935]
[10]
Kabelnitskaya LA, Petrova YВ, Troshina YA, Platonova NM, Melnichenko GA. Subacute thyroiditis. Probl Endokrinol (Mosk) 2006; 52(2): 35-43.
[PMID: 31627619]
[11]
Zhang Z, Li C. Follow-up of a case of subacute thyroiditis with uncommon thyroid (99m)Tc uptake. Arq Bras Endocrinol Metabol 2013; 57(8): 659-62.
[http://dx.doi.org/10.1590/S0004-27302013000800013] [PMID: 24343637]
[12]
Sato J, Uchida T, Komiya K, et al. Comparison of the therapeutic effects of prednisolone and nonsteroidal anti-inflammatory drugs in patients with subacute thyroiditis. Endocrine 2017; 55(1): 209-14.
[http://dx.doi.org/10.1007/s12020-016-1122-3] [PMID: 27688010]
[13]
Koirala KP, Sharma V. Treatment of acute painful thyroiditis with low dose prednisolone: A study on patients from Western Nepal. J Clin Diagn Res 2015; 9(9): MC01-3.
[http://dx.doi.org/10.7860/JCDR/2015/14893.6427] [PMID: 26500930]
[14]
Li L, Yue R, Zeng L, Wang S, Zhuo W, Sun Y. Efficacy and safety of Xiaochaihu decoction for subacute thyroiditis: A protocol of systematic review and meta-analysis. Medicine(Baltimore) 2020; 99(46): e23011-.
[15]
Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American thyroid association and American association of clinical endocrinologists. Thyroid 2011; 21(6): 593-646.
[http://dx.doi.org/10.1089/thy.2010.0417] [PMID: 21510801]
[16]
Chadha M, Mittal S. Subacute thyroiditis. In: Kumar Wangnoo S, Ahmad J, Asim Siddiqui M, Eds. Principles and practices of thyroid gland disorders(book). 2017; pp. 191-6.
[17]
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[18]
Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019; 10: ED000142.
[http://dx.doi.org/10.1002/14651858.ED000142] [PMID: 31643080]
[19]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[http://dx.doi.org/10.1007/s10654-010-9491-z] [PMID: 20652370]
[20]
Benbassat CA, Olchovsky D, Tsvetov G, Shimon I. Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. J Endocrinol Invest 2007; 30(8): 631-5.
[http://dx.doi.org/10.1007/BF03347442] [PMID: 17923793]
[21]
Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab 2003; 88(5): 2100-5.
[http://dx.doi.org/10.1210/jc.2002-021799] [PMID: 12727961]
[22]
Hepsen S, Akhanli P, Sencar ME, et al. The evaluation of low- and high-dose steroid treatments in subacute thyroiditis: A retrospective observational study. Endocr Pract 2021; 27(6): 594-600.
[http://dx.doi.org/10.1016/j.eprac.2020.11.009] [PMID: 34024631]
[23]
Higgins HP, Bayley TA, Diosy A. Suppression of endogenous TSH: a new treatment of subacute thyroiditis. J Clin Endocrinol Metab 1963; 23(3): 235-41.
[http://dx.doi.org/10.1210/jcem-23-3-235] [PMID: 13954406]
[24]
Hong X. Clinical observation on prednisolone acetate treating for 24 cases with subacute thyroiditis(abstract). Medical recapitulate. 2009; p. 07.
[25]
Niklaus-Müller E, Müllhaupt B, Perschak H. Steroid therapy and course of blood sedimentation rate in de Quervain’s thyroiditis. Schweiz Rundsch Med Prax 1994; 83(4): 95-100.
[PMID: 8115764]
[26]
Nishihara E, Amino N, Ohye H, et al. Extent of hypoechogenic area in the thyroid is related with thyroid dysfunction after subacute thyroiditis. J Endocrinol Invest 2009; 32(1): 33-6.
[http://dx.doi.org/10.1007/BF03345675] [PMID: 19337012]
[27]
Nordyke RA, Gilbert FI Jr, Lew C. Painful subacute thyroiditis in Hawaii. West J Med 1991; 155(1): 61-3.
[PMID: 1877232]
[28]
Sencar ME, Calapkulu M, Sakiz D, et al. An evaluation of the results of the steroid and non-steroidal anti-inflammatory drug treatments in subacute thyroiditis in relation to persistent hypothyroidism and recurrence. Sci Rep 2019; 9(1): 16899.
[http://dx.doi.org/10.1038/s41598-019-53475-w] [PMID: 31729433]
[29]
Duan L, Feng X, Zhang R, et al. Short-term versus 6-week prednisone in the treatment of subacute thyroiditis: A randomized controlled trial. Endocr Pract 2020; 26(8): 900-8.
[http://dx.doi.org/10.4158/EP-2020-0096] [PMID: 33471681]
[30]
Iitaka M, Momotani N, Ishii J, Ito K. Incidence of subacute thyroiditis recurrences after a prolonged latency: 24-year survey. J Clin Endocrinol Metab 1996; 81(2): 466-9.
[PMID: 8636251]
[31]
Ishidoh H, Kitaoka M. Staging of clinical course of subacute thyroiditis by high resolution ultrasonography: A study of clinical application on treatment of subacute thyroiditis. Japanese J Medical Ultrasonics 1996; 23(6): 15-20.
[32]
Jun GM, Mei SY, Xiang L, Min LZ. Comparison of oral prednisone and intrathyroidal injection of dexamethasone in treatment of patients with subacute thyroiditis (abstract). Ti Erh Chun i Ta Hsueh Hsueh Pao. 2003; 19: p. 3.
[33]
Kiso Y, Yoshida K, Kaise K, et al. Erythrocyte carbonic anhydrase-I concentrations in patients with Graves’ disease and subacute thyroiditis reflect integrated thyroid hormone levels over the previous few months. J Clin Endocrinol Metab 1991; 72(2): 515-8.
[http://dx.doi.org/10.1210/jcem-72-2-515] [PMID: 1899425]
[34]
Kitaoka H, Sakurada T, Fukazawa H, et al. An epidemiological study of subacute thyroiditis in northern Japan. Nippon Naibunpi Gakkai Zasshi 1985; 61(5): 554-70.
[http://dx.doi.org/10.1507/endocrine1927.61.5_554] [PMID: 4018309]
[35]
Kujat C, Dyck R, Brederhoff J, Pfannenstiel P. The diagnosis and therapy of de Quervain’s subacute thyroiditis. Dtsch Med Wochenschr 1991; 116(38): 1439-43.
[http://dx.doi.org/10.1055/s-2008-1063770] [PMID: 1893856]
[36]
Aristarkhov RV, Aristarkhov VG, Puzin DA, Ugolnikova EV. Comparative aspects of traditional therapy and laser therapy for the treatment of subacute thyroiditis de quervain. Лазерная медицина 2016; 20(4): 19-23.
[37]
Shunbin L, Qiu W, Zheng S, Shi W, Wang W. Clinical treatment of 100 patients with subacute thyroiditis. Chinese Gen Pract 2013; 12(11): 909-10.
[38]
Tauveron I, Thieblot P, Marcheix J. Recurrence of dequervains subacute thyroiditis after 12 years. Rev Med Interne 1991; 12(5): 396.
[http://dx.doi.org/10.1016/S0248-8663(05)80855-0] [PMID: 1771324]
[39]
Thewjitcharoen Y, Sirinate K, Siriwan B, Soontaree N, Thep H. Clinical features and outcomes of subacute thyroiditis in thai patients. J ASEAN Fed Endocr Soc 2015; 30(2): 125.
[40]
Turakulov IaKh, Nugmanova LB, Ismailov SI, Rustamova KhT, Ashurov RB. Indirect endolymphatic therapy with prednisolone in de Quervain’s subacute thyroiditis. Vestn Khir Im I I Grek 1996; 155(3): 54-5.
[PMID: 8966940]
[41]
Yamamoto M, Saito S, Kaise K, Kaise N, Yoshida K, Yoshinaga K. Changes in thyroid hormones by treatment with aspirin and prednisolone in subacute thyroiditis with hyperthyroidism. Tohoku J Exp Med 1979; 127(1): 85-95.
[http://dx.doi.org/10.1620/tjem.127.85] [PMID: 760253]
[42]
Yamamoto M, Saito S, Sakurada T, et al. Effect of prednisolone and salicylate on serum thyroglobulin level in patients with subacute thyroiditis. Clin Endocrinol (Oxf) 1987; 27(3): 339-44.
[http://dx.doi.org/10.1111/j.1365-2265.1987.tb01160.x] [PMID: 3427792]
[43]
Görges J, Ulrich J, Keck C, Müller-Wieland D, Diederich S, Janssen OE. Long-term outcome of subacute thyroiditis. Exp Clin Endocrinol Diabetes 2020; 128(11): 703-8.
[http://dx.doi.org/10.1055/a-0998-8035] [PMID: 31546269]
[44]
Clark DE, Nelsen TS, Raiman RJ. Subacute nonsuppurative thyroiditis treated with cortisone. J Am Med Assoc 1953; 151(7): 551-2.
[PMID: 13011045]
[45]
Furszyfer J, McConahey WM, Wahner HW, Kurland LT. Subacute (granulomatous) thyroiditis in Olmsted County, Minnesota. Mayo Clin Proc 1970; 45(5): 396-404.
[PMID: 5443236]
[46]
Hwang SC, Jap TS, Ho LT, Ching KN. Subacute thyroiditis-61 cases review. Zhonghua Yi Xue Za Zhi (Taipei) 1989; 43(2): 113-8.
[PMID: 2766065]
[47]
Kliachko VR. Treatment of nontoxic subacute thyroiditis with prednisolone and acth. Probl Endokrinol Gormonoter 1965; 11(11): 21-5.
[PMID: 14338209]
[48]
Xu S, Jiang Y, Jia A, et al. Comparison of the therapeutic effects of 15 mg and 30 mg initial dosage of prednisolone daily in patients with subacute thyroiditis: protocol for a multicenter, randomized, open, parallel control study. Trials 2020; 21(1): 418.
[http://dx.doi.org/10.1186/s13063-020-04337-8] [PMID: 32448401]
[49]
Arao T, Okada Y, Torimoto K, et al. Prednisolone dosing regimen for treatment of subacute thyroiditis. J UOEH 2015; 37(2): 103-10.
[http://dx.doi.org/10.7888/juoeh.37.103] [PMID: 26073499]
[50]
Erdem N, Erdogan M, Ozbek M, et al. Demographic and clinical features of patients with subacute thyroiditis: results of 169 patients from a single university center in Turkey. J Endocrinol Invest 2007; 30(7): 546-50.
[http://dx.doi.org/10.1007/BF03346347] [PMID: 17848836]
[51]
Qari FA, Maimani AA. Subacute thyroiditis in Western Saudi Arabia. Saudi Med J 2005; 26(4): 630-3.
[PMID: 15900374]
[52]
Kyriacou A, Syed A. Use of glucocorticoids in subacute thyroiditis (abstract) society for endocrinology BES 2017. 2017; 50: 403.
[53]
Schultz AL. Subacute diffuse thyroiditis. Clinical and laboratory findings 24 patients and the effect of treatment with adrenal corticoids. Postgrad Med 1961; 29(1): 76-85.
[http://dx.doi.org/10.1080/00325481.1961.11692340] [PMID: 13748851]
[54]
Li F, Wu Y, Chen L, Hu L, Liu X. Initial treatment combined with Prunella vulgaris reduced prednisolone consumption for patients with subacute thyroiditis. Ann Transl Med 2019; 7(3): 45.
[http://dx.doi.org/10.21037/atm.2019.01.07] [PMID: 30906749]
[55]
Kubota S, Nishihara E, Kudo T, Ito M, Amino N, Miyauchi A. Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. Thyroid 2013; 23(3): 269-72.
[http://dx.doi.org/10.1089/thy.2012.0459] [PMID: 23227861]
[56]
Won Jun K, Sangmo H, Myoung Sook S, Jin Yeob K. Survey on the steroid dose for patients with subacute thyroiditis in a Korean tertiary hospital(abstract). 17th European Congress of Endocrinology.
[57]
Tajiri J, Noguchi S, Morita M, Tamaru M, Murakami T, Murakami N. Serum sialic acid levels in the diagnosis and follow-up of subacute granulomatous thyroiditis. Endocr J 1993; 40(1): 83-7.
[http://dx.doi.org/10.1507/endocrj.40.83] [PMID: 7951500]
[58]
Birjandi A. Evaluation of the epidemiologic, clinical & laboratory features in subacute thyroiditis patient`s In shahrood & Mashhad (in about 25000 patients visited in clinic)(thesis): Islamic azad university Shahrood branch; 2014. Available at: https://www.virascience.com/thesis/676247/
[59]
Ataee Hoseinzadeh M. Evaluation of epidemiological , clinical and laboratory parameters in populations with subacute thyroiditis (SAT) in orumieh(with study of 25000 patient in clinic)(thesis): Islamic azad university - Shahrood branch 2014. Available at: https://www.virascience.com/thesis/author/495860/
[60]
Mizukoshi T, Noguchi S, Murakami T, Futata T, Yamashita H. Evaluation of recurrence in 36 subacute thyroiditis patients managed with prednisolone. Intern Med 2001; 40(4): 292-5.
[http://dx.doi.org/10.2169/internalmedicine.40.292] [PMID: 11334386]
[61]
Bennedbaek FN, Hegedüs L. The value of ultrasonography in the diagnosis and follow-up of subacute thyroiditis. Thyroid 1997; 7(1): 45-50.
[http://dx.doi.org/10.1089/thy.1997.7.45] [PMID: 9086570]
[62]
Tavakolian Arjmand A, Nouri M, Razavianzadeh N. Management of subacute thyroiditis with conventional high-dose prednisolone; Shooting a tree sparrow with a cannonball. Ann Clin Lab Res 2018; 06(01): 229.
[63]
Volpé R. The management of subacute (DeQuervain’s) thyroiditis. Thyroid 1993; 3(3): 253-5.
[http://dx.doi.org/10.1089/thy.1993.3.253] [PMID: 8257868]

Rights & Permissions Print Cite
Article Metrics
78
2
1
1
© 2024 Bentham Science Publishers | Privacy Policy